

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/835,537	04/16/2001	Carl R. Merril	PNC-004	5407
75	90 04/06/2006		EXAM	INER
M Elisa Lane			PRYOR, ALTON NATHANIEL	
Panacea Pharma 207 Perry Parky			ART UNIT	PAPER NUMBER
Gaithersburg, MD 20877			1616	
			DATE MAILED: 04/06/2000	6

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)		
	09/835,537	MERRIL ET AL.		
Office Action Summary	Examiner	Art Unit		
	Alton N. Pryor	1616		
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address		
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim till apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE!	the mailing date of this communication.  (35 U.S.C. § 133).		
Status				
1) Responsive to communication(s) filed on 12/19	<u>/06</u> .			
	action is non-final.			
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	i3 O.G. 213.		
Disposition of Claims				
<ul> <li>4) Claim(s) 19 and 21-35 is/are pending in the appending of the above claim(s) is/are withdraw</li> <li>5) Claim(s) is/are allowed.</li> <li>6) Claim(s) 19 and 21-35 is/are rejected.</li> <li>7) Claim(s) is/are objected to.</li> <li>8) Claim(s) are subject to restriction and/or</li> </ul>	n from consideration.			
Application Papers				
9) The specification is objected to by the Examine	•			
10) The drawing(s) filed on is/are: a) acce		Examiner.		
Applicant may not request that any objection to the				
Replacement drawing sheet(s) including the correcti	on is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).		
11) The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.		
Priority under 35 U.S.C. § 119				
12) Acknowledgment is made of a claim for foreign  a) All b) Some * c) None of:  1. Certified copies of the priority documents  2. Certified copies of the priority documents  3. Copies of the certified copies of the prior application from the International Bureau  * See the attached detailed Office action for a list of	s have been received. s have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No d in this National Stage		
Attachment(s)	Δ\	/DTO 442)		
Notice of References Cited (PTO-892)   Notice of Draftsperson's Patent Drawing Review (PTO-948)   Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)   Paper No(s)/Mail Date	4)  Interview Summary Paper No(s)/Mail Da 5)  Notice of Informal Pa			

Application/Control Number: 09/835,537 Page 2

Art Unit: 1616

## **DETAILED ACTION**

I. Rejection of claims 19,21-35 under 35 USC 112, 1<sup>st</sup> paragraph will be maintained in light of amendment filed 12/19/05. Applicant argues: 1) Guanidinoacetate is not a salt and is not the same as guanidine acetate which is a salt; and 2) Rejection does not provide a basis for limiting the claims to only named prion diseases. Examiner argues: Guanidinoacetate and guanidine acetate are equivalent compounds arising from a combination of guanidine and acetate; 2) There exist basis for limiting Applicant to instant named prion diseases. Basis lie within what is disclosed in the specification, particularly working examples. Claims are not in commensurate in scope with examples disclosed in the specification.

II. Rejection of claims 19,22-25,27-29 under 35 USC 102(e) as being anticipated and claim 30 under 35 USC 103(a) as being obvious over Kaddurah-Daouk will be maintained for reason on record and reasons as follows. Applicant argues: 1) Guanidinoacetate is not a salt and is not the same a guanidine acetate which is a salt (Applicant references USPN 5324731 for support). Examiner argues: Guanidinoacetate and guanidine acetate are equivalent compounds arising from a combination of guanidine and acetate.

## Telephonic Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alton N. Pryor whose telephone number is 571-272-0621. The examiner can normally be reached on 8:00 a.m. - 4:30 p.m..

Art Unit: 1616

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Primary Examiner

AU 1616